Transcode Therapeutics Inc
NASDAQ:RNAZ

Watchlist Manager
Transcode Therapeutics Inc Logo
Transcode Therapeutics Inc
NASDAQ:RNAZ
Watchlist
Price: 7.53 USD -0.86% Market Closed
Market Cap: 6.9m USD

Intrinsic Value

RNAZ doesn't have a meaningful market cap.

There is not enough data to reliably calculate the intrinsic value of RNAZ.

The Intrinsic Value is calculated as the average of DCF and Relative values:

RNAZ Intrinsic Value
Not Available
Base Case Scenario
Compare RNAZ to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about RNAZ?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Transcode Therapeutics Inc

Current Assets 4.8m
Cash & Short-Term Investments 2.8m
Receivables 198.3k
Other Current Assets 1.7m
Non-Current Assets 475.6k
PP&E 19.9k
Other Non-Current Assets 455.7k
Current Liabilities 3m
Accounts Payable 1.8m
Accrued Liabilities 1.2m
Non-Current Liabilities 832.9k
Other Non-Current Liabilities 832.9k
Efficiency

Free Cash Flow Analysis
Transcode Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Transcode Therapeutics Inc

Revenue
0 USD
Operating Expenses
-17m USD
Operating Income
-17m USD
Other Expenses
-10.1m USD
Net Income
-27.2m USD
Fundamental Scores

RNAZ Profitability Score
Profitability Due Diligence

Transcode Therapeutics Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

Exceptional 3Y Average ROIC
Exceptional 3Y Average ROE
ROIC is Increasing
Low 3Y Average Gross Margin
54/100
Profitability
Score

Transcode Therapeutics Inc's profitability score is 54/100. The higher the profitability score, the more profitable the company is.

RNAZ Solvency Score
Solvency Due Diligence

Transcode Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Low Altman Z-Score
38/100
Solvency
Score

Transcode Therapeutics Inc's solvency score is 38/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RNAZ Price Targets Summary
Transcode Therapeutics Inc

There are no price targets for RNAZ.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Transcode Therapeutics Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for RNAZ is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

RNAZ Insider Trading
Buy and sell transactions by insiders